27556586|t|Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi - Challenge
27556586|a|Dogs represent the most important domestic reservoir of L. chagasi (syn. L. infantum). A vaccine against canine visceral leishmaniasis (CVL) would be an important tool for decreasing the anxiety related to possible L. chagasi infection and for controlling human visceral leishmaniasis (VL). Because the sand fly salivary proteins are potent immunogens obligatorily co-deposited during transmission of Leishmania parasites, their inclusion in an anti-Leishmania vaccine has been investigated in past decades. We investigated the immunogenicity of the "LbSapSal" vaccine (L. braziliensis antigens, saponin as adjuvant, and Lutzomyia longipalpis salivary gland extract) in dogs at baseline (T0), during the post-vaccination protocol (T3rd) and after early (T90) and late (T885) times following L. chagasi - challenge. Our major data indicated that immunization with " LbSapSal " is able to induce biomarkers characterized by enhanced amounts of type I (tumor necrosis factor [TNF]-α, interleukin [IL]-12, interferon [IFN]-γ) cytokines and reduction in type II cytokines (IL-4 and TGF-β), even after experimental challenge. The establishment of a prominent pro-inflammatory immune response after " LbSapSal " immunization supported the increased levels of nitric oxide production, favoring a reduction in spleen parasitism (78.9%) and indicating long-lasting protection against L. chagasi infection. In conclusion, these results confirmed the hypothesis that the " LbSapSal " vaccination is a potential tool to control the Leishmania chagasi infection.
27556586	0	6	Impact	T080	C4049986
27556586	10	26	LbSapSal Vaccine	T121,T129	C0042210
27556586	30	36	Canine	T015	C1280551
27556586	37	50	Immunological	T169	C0205470
27556586	55	70	Parasitological	T080	C0205468
27556586	97	115	Leishmania chagasi	T204	C0446195
27556586	118	127	Challenge	T058	C0805586
27556586	128	132	Dogs	T015	C0012984
27556586	184	194	L. chagasi	T204	C0446195
27556586	201	212	L. infantum	T204	C0023272
27556586	217	224	vaccine	T121,T129	C0042210
27556586	233	239	canine	T015	C1280551
27556586	240	262	visceral leishmaniasis	T047	C0023290
27556586	264	267	CVL	T047	C0023290
27556586	315	322	anxiety	T033	C0003467
27556586	343	363	L. chagasi infection	T047	C1400587
27556586	384	389	human	T016	C0086418
27556586	390	412	visceral leishmaniasis	T047	C0023290
27556586	414	416	VL	T047	C0023290
27556586	431	439	sand fly	T204	C0036158
27556586	440	457	salivary proteins	T116,T123	C0036100
27556586	469	479	immunogens	T129	C0003320
27556586	513	525	transmission	T070	C1521797
27556586	529	549	Leishmania parasites	T204	C1095819
27556586	573	596	anti-Leishmania vaccine	T121,T129	C1548483
27556586	627	634	decades	T081	C2981279
27556586	656	670	immunogenicity	T038	C4277607
27556586	678	696	"LbSapSal" vaccine	T121,T129	C0042210
27556586	698	713	L. braziliensis	T204	C0023271
27556586	714	722	antigens	T129	C0003320
27556586	724	731	saponin	T109	C0520481
27556586	735	743	adjuvant	T121,T129	C0001551
27556586	749	770	Lutzomyia longipalpis	T204	C0322761
27556586	771	785	salivary gland	T023	C0036098
27556586	786	793	extract	T167	C2828366
27556586	798	802	dogs	T015	C0012984
27556586	832	848	post-vaccination	T079	C1254367
27556586	919	929	L. chagasi	T204	C0446195
27556586	932	941	challenge	T058	C0805586
27556586	973	985	immunization	T061	C0020971
27556586	993	1001	LbSapSal	T121,T129	C0042210
27556586	1022	1032	biomarkers	T201	C0005516
27556586	1070	1076	type I	T116,T129	C0041368
27556586	1078	1107	tumor necrosis factor [TNF]-α	T116,T129	C1456820
27556586	1109	1128	interleukin [IL]-12	T116,T121,T129	C0123759
27556586	1130	1148	interferon [IFN]-γ	T116,T121,T129	C0021745
27556586	1150	1159	cytokines	T116,T129	C0079189
27556586	1177	1194	type II cytokines	T116,T129	C0079189
27556586	1196	1200	IL-4	T116,T129	C0021758
27556586	1205	1210	TGF-β	T116,T123	C0040690
27556586	1237	1246	challenge	T058	C0805586
27556586	1281	1297	pro-inflammatory	T169	C0333348
27556586	1298	1313	immune response	T042	C0301872
27556586	1322	1330	LbSapSal	T121,T129	C0042210
27556586	1333	1345	immunization	T061	C0020971
27556586	1380	1392	nitric oxide	T121,T123,T197	C0028128
27556586	1393	1403	production	T052	C1883254
27556586	1429	1435	spleen	T023	C0037993
27556586	1436	1446	parasitism	T070	C0677482
27556586	1483	1493	protection	T033	C1545588
27556586	1502	1522	L. chagasi infection	T047	C1400587
27556586	1567	1577	hypothesis	T078	C1512571
27556586	1589	1597	LbSapSal	T121,T129	C0042210
27556586	1600	1611	vaccination	T061	C0042196
27556586	1627	1631	tool	T169	C0449851
27556586	1635	1642	control	T080	C0243148
27556586	1647	1675	Leishmania chagasi infection	T047	C1400587